Loading
A phase 3 trial of Venetoclax in multiple myeloma and non-hodgkin lymphoma, run by AbbVie, active and no longer recruiting.
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is a phase 3 interventional study registered as NCT03844048 by AbbVie, with 165 participants enrolled, started 2019-09-06 and due to reach its primary completion in 2027-08. Interventions recorded: Venetoclax. Conditions listed: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Venetoclax, Multiple myeloma, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Non-Hodgkin lymphoma (all types), Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/